AQR Capital Management LLC Sells 544,524 Shares of Cencora, Inc. $COR

AQR Capital Management LLC reduced its position in shares of Cencora, Inc. (NYSE:COR) by 38.2% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 881,466 shares of the company’s stock after selling 544,524 shares during the quarter. AQR Capital Management LLC’s holdings in Cencora were worth $264,308,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Atlantic Edge Private Wealth Management LLC lifted its position in Cencora by 70.0% in the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after acquiring an additional 35 shares in the last quarter. Vermillion & White Wealth Management Group LLC boosted its position in shares of Cencora by 69.4% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock valued at $31,000 after buying an additional 43 shares during the last quarter. Twin Peaks Wealth Advisors LLC bought a new stake in shares of Cencora in the 2nd quarter worth $52,000. Caitong International Asset Management Co. Ltd purchased a new stake in Cencora in the 2nd quarter valued at about $61,000. Finally, ANTIPODES PARTNERS Ltd bought a new position in shares of Cencora during the 2nd quarter worth approximately $61,000. 97.52% of the stock is currently owned by institutional investors.

Cencora Stock Up 0.4%

Shares of COR opened at $345.86 on Friday. The firm has a market cap of $67.09 billion, a P/E ratio of 43.50, a P/E/G ratio of 1.63 and a beta of 0.63. The stock has a 50 day simple moving average of $343.29 and a two-hundred day simple moving average of $311.20. Cencora, Inc. has a 1 year low of $223.92 and a 1 year high of $377.54. The company has a debt-to-equity ratio of 4.32, a current ratio of 0.90 and a quick ratio of 0.55.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.79 by $0.05. The business had revenue of $83.73 billion during the quarter, compared to analyst estimates of $83.36 billion. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The company’s revenue was up 5.9% on a year-over-year basis. During the same period in the prior year, the business posted $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 14th were given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend was Friday, November 14th. This is an increase from Cencora’s previous quarterly dividend of $0.55. Cencora’s dividend payout ratio is currently 30.19%.

Wall Street Analyst Weigh In

COR has been the subject of several recent analyst reports. TD Cowen upped their target price on Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a report on Monday, November 10th. Wall Street Zen lowered Cencora from a “buy” rating to a “hold” rating in a report on Friday, November 28th. JPMorgan Chase & Co. lifted their price objective on Cencora from $344.00 to $417.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. Mizuho upped their price target on shares of Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. Finally, Wells Fargo & Company lifted their price target on Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a research report on Tuesday, November 11th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, Cencora has an average rating of “Moderate Buy” and a consensus target price of $373.50.

Insider Transactions at Cencora

In other Cencora news, CEO Robert P. Mauch sold 5,097 shares of the company’s stock in a transaction on Monday, October 20th. The shares were sold at an average price of $326.80, for a total value of $1,665,699.60. Following the completion of the transaction, the chief executive officer directly owned 37,940 shares in the company, valued at approximately $12,398,792. This represents a 11.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman Steven H. Collis sold 31,350 shares of the firm’s stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the completion of the sale, the chairman owned 305,913 shares of the company’s stock, valued at $88,671,942.18. This trade represents a 9.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 46,640 shares of company stock worth $14,099,338. 10.80% of the stock is owned by company insiders.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.